세계의 동물용 재생의료 시장 - 산업 규모, 점유율, 동향, 기회, 예측(2019-2029년)

Global Veterinary Regenerative Medicine Market was valued at USD 259.49 million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 10.75% through 2029. The Global Veterinary Regenerative Medicine Market is a rapidly evolving sector poised to revolutionize veterinary healthcare by leveraging innovative technologies and cutting-edge research in regenerative medicine. This market encompasses a wide array of therapeutic approaches aimed at restoring, repairing, or replacing damaged tissues and organs in animals, thereby offering new avenues for treating a variety of diseases and injuries. Key drivers propelling the growth of this market include the increasing prevalence of chronic diseases and musculoskeletal disorders in companion animals, the rising demand for advanced veterinary care, and growing investments in research and development activities by key industry players. Stem cell therapy, platelet-rich plasma (PRP) therapy, tissue engineering, and gene therapy are among the prominent modalities driving advancements in veterinary regenerative medicine. Stem cell therapy, in particular, holds immense promise for treating conditions such as osteoarthritis, tendon injuries, and degenerative joint diseases in animals, with mesenchymal stem cells being the most commonly utilized cell type.

The advent of novel technologies like 3D bioprinting has facilitated the development of customized tissue constructs and implants, enabling precise tissue regeneration and functional restoration in veterinary patients. The companion animal segment dominates the veterinary regenerative medicine market, fueled by the growing pet ownership rates worldwide and the rising demand for advanced therapeutic solutions to enhance the quality of life of companion animals. However, the livestock sector is also witnessing significant adoption of regenerative medicine techniques to address health challenges and improve productivity in livestock farming. North America and Europe currently lead the global veterinary regenerative medicine market, driven by robust research infrastructure, increasing veterinary expenditures, and supportive regulatory frameworks. Nevertheless, emerging economies in the Asia-Pacific region are anticipated to exhibit lucrative growth opportunities, attributed to the expanding pet population, rising disposable incomes, and escalating investments in animal healthcare infrastructure. Despite the promising growth prospects, challenges such as high treatment costs, regulatory complexities, and ethical considerations surrounding the use of stem cells in veterinary medicine remain areas of concern.

Key Market Drivers

Rising Prevalence of Chronic Diseases and Musculoskeletal Disorders

The rising prevalence of chronic diseases and musculoskeletal disorders among animals is a significant factor driving the growth of the Global Veterinary Regenerative Medicine Market. Companion animals, including dogs, cats, and horses, are increasingly susceptible to a variety of chronic conditions that compromise their quality of life and mobility. Osteoarthritis, a degenerative joint disease characterized by inflammation and cartilage degradation, is one of the most common chronic conditions affecting both companion animals and livestock. Additionally, tendon injuries, ligament tears, and musculoskeletal disorders such as hip dysplasia and intervertebral disc disease are prevalent among certain breeds of dogs and horses.

Several factors contribute to the rising prevalence of these conditions, including genetic predispositions, aging populations, obesity, and increased physical activity levels among pets. As pet ownership rates continue to rise globally and animals are increasingly regarded as members of the family, pet owners are seeking advanced treatment options to alleviate pain, improve mobility, and enhance the overall well-being of their beloved companions. Traditional treatment modalities such as pain management medications and surgical interventions may provide temporary relief but often fail to address the underlying cause of the condition or promote long-term healing. In contrast, regenerative medicine offers a promising alternative by harnessing the body's natural healing mechanisms to regenerate and repair damaged tissues and organs.

Stem cell therapy, in particular, has emerged as a leading regenerative medicine modality for treating chronic diseases and musculoskeletal disorders in animals. Mesenchymal stem cells, derived from sources such as adipose tissue, bone marrow, or umbilical cord blood, have the ability to differentiate into various cell types and exert potent anti-inflammatory and regenerative effects. When administered to animals with conditions such as osteoarthritis or tendon injuries, stem cells can promote tissue repair, reduce inflammation, and improve overall joint function.

Platelet-rich plasma (PRP) therapy is another regenerative medicine approach gaining traction in veterinary practice. By harnessing the healing properties of platelets found in the animal's blood, PRP therapy can accelerate tissue regeneration and enhance the body's natural healing response. This therapy is particularly effective for treating soft tissue injuries, ligament tears, and tendonitis in animals. As the prevalence of chronic diseases and musculoskeletal disorders continues to rise, the demand for advanced therapeutic solutions like regenerative medicine is expected to increase significantly. This trend is driving investment in research and development efforts aimed at expanding the therapeutic capabilities of regenerative medicine and improving outcomes for veterinary patients worldwide.

Growing Demand for Advanced Veterinary Care

The growing demand for advanced veterinary care is a significant driver fueling the expansion of the Global Veterinary Regenerative Medicine Market. Pet owners worldwide are increasingly seeking sophisticated medical treatments and interventions for their animal companions, mirroring the trend seen in human healthcare. This shift is driven by various factors, including the rising awareness of pet health issues, the strengthening emotional bond between humans and animals, and the desire to provide the best possible care for pets.

Pet owners today view their animals as integral members of the family and are willing to invest in their health and well-being accordingly. As a result, there is a growing demand for cutting-edge veterinary treatments that offer effective solutions for a wide range of health conditions and injuries. Traditional treatment options, while often effective, may have limitations in addressing certain chronic diseases and musculoskeletal disorders comprehensively.

Regenerative medicine presents a promising alternative by harnessing the body's natural healing processes to promote tissue repair and regeneration. Stem cell therapy, platelet-rich plasma (PRP) therapy, and other regenerative modalities offer novel approaches to treating conditions such as osteoarthritis, ligament injuries, and degenerative joint diseases in animals. These therapies not only alleviate pain and improve mobility but also target the underlying cause of the condition, leading to more sustainable and long-lasting results.

Advancements in veterinary regenerative medicine have expanded the scope of treatment options available to pet owners, providing hope for cases that were previously considered untreatable or required invasive surgical interventions. For example, stem cell therapy has shown promising results in promoting cartilage regeneration and reducing inflammation in animals with osteoarthritis, offering a viable alternative to traditional pain management strategies. Additionally, the growing availability of regenerative medicine treatments in veterinary clinics and specialty hospitals has made these advanced therapies more accessible to pet owners. Veterinarians are increasingly incorporating regenerative medicine into their practice, recognizing its potential to improve outcomes and enhance the quality of life for their patients.

As the demand for advanced veterinary care continues to rise, fueled by the evolving attitudes towards pet health and the increasing emphasis on preventive medicine and personalized treatment approaches, the market for veterinary regenerative medicine is expected to witness significant growth. Investment in research and development, coupled with supportive regulatory frameworks, will further drive innovation in this field, leading to the development of new and improved regenerative therapies for veterinary use.

Technological Advancements in Regenerative Medicine

Technological advancements in regenerative medicine play a pivotal role in driving the growth of the Global Veterinary Regenerative Medicine Market. These innovations have revolutionized veterinary healthcare by expanding treatment options, improving outcomes, and enhancing the overall efficacy of regenerative therapies for animals. Technological advancements have deepened our understanding of regenerative processes at the cellular and molecular levels. High-resolution imaging techniques, such as confocal microscopy and live-cell imaging, allow researchers to visualize and study cellular behaviors and interactions in real-time, providing invaluable insights into tissue regeneration and repair mechanisms. This enhanced understanding enables the development of more targeted and effective regenerative medicine therapies for veterinary use.

Advances in technologies such as next-generation sequencing (NGS), gene editing, and proteomics have paved the way for precision medicine approaches in veterinary regenerative medicine. By analyzing the genetic and molecular profiles of individual animals, veterinarians can tailor regenerative therapies to the specific needs and characteristics of each patient, maximizing treatment efficacy and minimizing adverse effects. Precision medicine holds great promise for optimizing regenerative medicine outcomes and advancing personalized veterinary care.

Technological innovations have led to the development of novel therapeutic modalities in regenerative medicine, expanding the range of treatment options available to veterinary practitioners. For example, 3D bioprinting technology allows for the precise fabrication of complex tissue constructs and implants, enabling customized regenerative solutions for various veterinary applications. Similarly, advancements in biomaterials science have led to the development of scaffolds and matrices that mimic the extracellular environment and support tissue regeneration in vivo.

Technological advancements have facilitated the development of advanced delivery systems for regenerative medicine therapies, improving their safety, efficacy, and targeted delivery to the site of injury or disease. Nanotechnology-based drug delivery systems, for instance, enable the controlled release of therapeutic agents, such as growth factors or stem cells, at the desired location within the body. These advancements in delivery systems enhance the therapeutic potential of regenerative medicine treatments and contribute to better clinical outcomes in veterinary patients.

Key Market Challenges

High Treatment Costs

One of the primary challenges facing the veterinary regenerative medicine market is the high cost associated with treatment. Regenerative medicine therapies, such as stem cell therapy and platelet-rich plasma (PRP) therapy, often require specialized equipment, trained personnel, and costly procedures, leading to significant financial barriers for pet owners and veterinary clinics. The high upfront costs of regenerative medicine treatments may deter some pet owners from pursuing these advanced therapies, particularly in cases where alternative treatment options are available at lower costs.

Regulatory Complexities

Navigating regulatory frameworks and obtaining approvals for regenerative medicine products can be complex and time-consuming, posing a significant challenge for market players. Regulatory agencies vary in their requirements for the approval and commercialization of regenerative medicine therapies, leading to inconsistencies and uncertainties in the regulatory landscape. Obtaining regulatory approvals for new therapies may involve extensive preclinical and clinical studies, which can be costly and time intensive. Additionally, the classification of regenerative medicine products as biologics, medical devices, or pharmaceuticals further complicates the regulatory process, requiring careful navigation by industry stakeholders.

Limited Access to Specialized Equipment and Expertise

Access to specialized equipment and expertise required for performing regenerative medicine treatments can be limited, particularly in rural or underserved areas. Veterinary clinics may lack the necessary infrastructure, training, or resources to offer regenerative medicine therapies, leading to disparities in access to advanced treatments for animal patients. Furthermore, the expertise required to perform regenerative medicine procedures, such as cell isolation and culture techniques, may be limited to specialized facilities or trained personnel, further restricting access to these therapies for veterinary patients.

Key Market Trends

Development of Novel Therapeutic Modalities

The development of novel therapeutic modalities is playing a crucial role in propelling the growth of the Global Veterinary Regenerative Medicine Market. These innovative approaches are revolutionizing veterinary healthcare by expanding treatment options, improving outcomes, and enhancing the overall efficacy of regenerative therapies for animals. One of the most groundbreaking advancements in regenerative medicine is 3D bioprinting technology. This cutting-edge approach enables the precise fabrication of complex tissue constructs and implants using biocompatible materials and living cells. In veterinary medicine, 3D bioprinting holds immense promise for creating customized regenerative solutions tailored to the specific needs of individual animals. Whether it's reconstructing bone tissue in a fracture or repairing damaged cartilage in a joint, 3D bioprinting offers unprecedented opportunities for tissue regeneration and functional restoration in veterinary patients.

Advances in biomaterials science have led to the development of innovative scaffolds, matrices, and hydrogels that mimic the natural extracellular environment and support tissue regeneration in vivo. These biomaterials serve as scaffolds for cell attachment, proliferation, and differentiation, providing a conducive microenvironment for tissue repair and regeneration. In veterinary regenerative medicine, biomaterials-based approaches are being explored for applications ranging from wound healing and tissue engineering to drug delivery and organ transplantation, offering new avenues for improving the health and well-being of animals.

Based Drug Delivery Systems: Nanotechnology-based drug delivery systems are revolutionizing the field of veterinary regenerative medicine by enabling the controlled release of therapeutic agents, such as growth factors, cytokines, and stem cells, at the desired location within the body. These nanocarriers protect the payload from degradation, prolonging its circulation time and enhancing its bioavailability and therapeutic efficacy. Nanotechnology-based delivery systems hold promise for targeted delivery of regenerative therapies to specific tissues or organs, minimizing off-target effects and maximizing treatment outcomes in veterinary patients.

Advancements in Delivery Systems

Advancements in delivery systems are playing a pivotal role in boosting the Global Veterinary Regenerative Medicine Market. These innovations are revolutionizing the way regenerative therapies are administered to animals, improving their safety, efficacy, and targeted delivery to the site of injury or disease. Nanotechnology-based drug delivery systems have emerged as a game-changer in veterinary regenerative medicine. These nanocarriers, typically nanoparticles or liposomes, are engineered to encapsulate therapeutic agents such as growth factors, cytokines, or stem cells, and deliver them to the desired location within the body. By exploiting the unique properties of nanomaterials, such as their small size, large surface area, and ability to penetrate biological barriers, nanotechnology-based delivery systems offer precise control over drug release kinetics, prolonging circulation time and enhancing bioavailability. This targeted delivery approach minimizes off-target effects and maximizes therapeutic efficacy, making nanotechnology-based delivery systems invaluable tools for enhancing regenerative medicine treatments in veterinary patients.

Injectable hydrogels and scaffolds are another innovative delivery system that holds promise for veterinary regenerative medicine. These biomaterial-based constructs can be injected directly into the site of injury or disease, where they undergo gelation and provide a three-dimensional matrix for cell attachment, proliferation, and differentiation. Injectable hydrogels and scaffolds offer several advantages, including minimally invasive administration, conformability to irregular tissue shapes, and tunable mechanical properties. They can be loaded with therapeutic agents, such as stem cells or growth factors, to enhance tissue regeneration and repair. Injectable hydrogels and scaffolds are particularly well-suited for applications such as wound healing, tissue engineering, and cartilage repair in veterinary patients.

Advances in targeted delivery vehicles are enabling precise localization of regenerative therapies to specific tissues or organs within the body. Targeted delivery vehicles, such as liposomes or nanoparticles, can be surface functionalized with ligands or antibodies that selectively bind to receptors or markers expressed on the surface of target cells or tissues. This targeted approach allows for enhanced accumulation of therapeutic agents at the site of injury or disease, while minimizing systemic exposure and off-target effects. Targeted delivery vehicles hold promises for improving the efficacy and safety of regenerative medicine treatments in veterinary patients, offering a personalized and precision medicine approach to veterinary healthcare.

Segmental Insights

Animal Type Insights

Based on the animal type, large animals segment emerged as the dominant segment in the global veterinary regenerative medicine market in 2023. Large animals, such as horses, cattle, and pigs, are often subjected to strenuous activities or intensive farming practices, making them more susceptible to musculoskeletal injuries and degenerative diseases. As a result, there is a higher demand for regenerative medicine therapies to address these conditions and promote tissue repair and regeneration in large animals. Also the dominance of the large animals segment in the Global Veterinary Regenerative Medicine Market underlines the importance of regenerative medicine in promoting the health, performance, and economic viability of these animals across various sectors and industries.

Product Insights

In 2023, stem cells emerge as the dominant segment in the global Veterinary Regenerative Medicine Market. Stem cell therapy offers unparalleled potential in treating various ailments in animals, ranging from orthopedic injuries to degenerative diseases. Its versatility lies in the ability to differentiate into multiple cell types, aiding in tissue regeneration and repair. Moreover, advancements in stem cell research have led to the development of innovative techniques and products tailored for veterinary use, enhancing treatment efficacy and safety. The growing awareness among pet owners about regenerative medicine's benefits and the increasing adoption of companion animals further propel the demand for stem cell therapies. Consequently, the stem cell segment establishes its dominance by offering promising solutions for enhancing animal health and quality of life globally.

Regional Insights

North America emerged as the dominant region in the global veterinary regenerative medicine market in 2023, holding the largest market share. stringent government regulations and vaccination mandates in North America have significantly contributed to the region's dominance in the market. Many countries within North America, including the United States and Canada, have implemented mandatory rabies vaccination laws for domestic animals, such as dogs and cats. These regulations require pet owners to ensure their animals are vaccinated against rabies regularly, driving a consistent demand for veterinary vaccines in the region. The dominance of North America in the Global Veterinary Regenerative Medicine Market in 2023 underscores the region's commitment to rabies prevention, strong regulatory framework, advanced healthcare infrastructure, and growing pet ownership culture.

Key Market Players

Boehringer Ingelheim International GmbH

Zoetis Inc.

Dechra Pharmaceuticals PLC

Integra LifeSciences Incorporation

Vetherapy

VetStem, Inc.

Ardent Animal Health, LLC

Enso Discoveries, LLC

Animal Cell Therapies, Inc.

Vetbiologics LLC

Report Scope:

In this report, the Global Veterinary Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Regenerative Medicine Market, By Animal Type:

Small Animals Large Animals

Veterinary Regenerative Medicine Market, By Product:

Stem Cells Others

Veterinary Regenerative Medicine Market, By Application:

Orthopedics Trauma/Wound Care Others

Veterinary Regenerative Medicine Market, By End Use:

Veterinary Hospitals/Clinics Veterinary Research Institutes

Veterinary Regenerative Medicine Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Regenerative Medicine Market.

Available Customizations:

Global Veterinary Regenerative Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Regenerative Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Small Animals, Large Animals)
  • 5.2.2. By Product (Stem Cells, Others)
  • 5.2.3. By Application (Orthopedics, Trauma/Wound Care, Others)
  • 5.2.4. By End-Use (Veterinary Hospitals/Clinics, Veterinary Research Institutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2023)
• 5.3. Market Map

6. Asia Pacific Veterinary Regenerative Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By End-Use
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Veterinary Regenerative Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-Use
  • 6.3.2. India Veterinary Regenerative Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-Use
  • 6.3.3. Australia Veterinary Regenerative Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-Use
  • 6.3.4. Japan Veterinary Regenerative Medicine Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Animal Type
      • 6.3.4.2.2. By Product
      • 6.3.4.2.3. By Application
      • 6.3.4.2.4. By End-Use
  • 6.3.5. South Korea Veterinary Regenerative Medicine Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Animal Type
      • 6.3.5.2.2. By Product
      • 6.3.5.2.3. By Application
      • 6.3.5.2.4. By End-Use

7. Europe Veterinary Regenerative Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By End-Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Veterinary Regenerative Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-Use
  • 7.3.2. Germany Veterinary Regenerative Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-Use
  • 7.3.3. Spain Veterinary Regenerative Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-Use
  • 7.3.4. Italy Veterinary Regenerative Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-Use
  • 7.3.5. United Kingdom Veterinary Regenerative Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-Use

8. North America Veterinary Regenerative Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By End-Use
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Veterinary Regenerative Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-Use
  • 8.3.2. Mexico Veterinary Regenerative Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-Use
  • 8.3.3. Canada Veterinary Regenerative Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-Use

9. South America Veterinary Regenerative Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By End-Use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Veterinary Regenerative Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-Use
  • 9.3.2. Argentina Veterinary Regenerative Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-Use
  • 9.3.3. Colombia Veterinary Regenerative Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-Use

10. Middle East and Africa Veterinary Regenerative Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By End-Use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Veterinary Regenerative Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-Use
  • 10.3.2. Saudi Arabia Veterinary Regenerative Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-Use
  • 10.3.3. UAE Veterinary Regenerative Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-Use
  • 10.3.4. Egypt Veterinary Regenerative Medicine Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Animal Type
      • 10.3.4.2.2. By Product
      • 10.3.4.2.3. By Application
      • 10.3.4.2.4. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Veterinary Regenerative Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Boehringer Ingelheim International GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Zoetis Inc.
• 15.3. Dechra Pharmaceuticals PLC
• 15.4. Integra LifeSciences Incorporation
• 15.5. Vetherapy
• 15.6. VetStem, Inc.
• 15.7. Ardent Animal Health, LLC
• 15.8. Enso Discoveries, LLC
• 15.9. Animal Cell Therapies, Inc.
• 15.10. Vetbiologics. LLC

16. Strategic Recommendations

17. About Us & Disclaimer